ABIONYX Pharma Announces Its Financial Calendar for the Year 2025

TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announces its financial calendar for 2025.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250113509882/en/

NewCap
Investor relations
Nicolas Fossiez
Louis-Victor Delouvrier
[email protected]
+33 (0)1 44 71 98 53

NewCap
Media relations
Arthur Rouillé
[email protected]
+33 (0)1 44 71 00 15

Source: ABIONYX Pharma

You May Also Be Interested In

• Lark Electric Joins American Gridwork Partners in Strategic Partnership to Accelerate Regional Growth and Expand Industrial Automation Capabilities
• KBRA Assigns A- with Stable Outlook to Monterey Peninsula Airport District Airport Revenue Bonds and TIFIA Loan
• The Modern Shrine Turns Ancient Pattern Systems Into AI Decision Tools After Testing the Method Live